weight loss on tirzepatide 3 months vs. 6 months Paving the Road to Tirzepatide

Think of weight loss like a hike

doi: 10.1093/jnci/djn330 4 Unger-SaldanaK

Cardiovascular benefits Certain GLP-1 agonists (such as semaglutide and liraglutide) have been shown to reduce the risk of major cardiovascular events, particularly in people with existing heart disease or high cardiovascular risk

Without lifestyle changes, weight regain is possible

Less than 7% of clinical trial participants opted to discontinue Wegovy after adverse side effects

In addition, commercially available products may present other limitations : Fixed dosing that does not allow for gradual titration Lack of preservative-free or dye-free options Absence of certain medications in oral form in the United States Limited flexibility in combining therapies to match multisystem symptom patterns In many MCAS cases, therapies cannot be fully implemented using commercially manufactured products alone